Tech Company Financing Transactions
Diffusion Pharmaceuticals Funding Round
Diffusion Pharmaceuticals secured a $5 million funding round on 6/21/2013. Backers included private investors.
Transaction Overview
Company Name
Announced On
6/21/2013
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds will support the Company's ongoing Phase 2 clinical trial for its lead drug, trans sodium crocetinate (TSC). Enrollment is closed and TSC dosing is complete in all 59 patients who have newly diagnosed primary brain cancer (glioblastoma multiforme or GBM).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1317 Carlton Ave. 200
Charlottesville, VA 22902
USA
Charlottesville, VA 22902
USA
Phone
Website
Email Address
Overview
Improving the results of cancer treatments such as radiation therapy and chemotherapy in multiple FDA Orphan-designated solid tumor indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Kalergis
Chief Medical Officer
David Jones
Chief Scientific Officer
John Gainer
VP - Bus. Development
William Hornung
VP - General Counsel
Thomas Byrne
VP - Operations
Harry Cook
Browse more venture capital transactions:
Prev: 6/21/2013: Better ATM Services venture capital transaction
Next: 6/21/2013: Mnemosyne Pharmaceuticals venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs